Cargando…
P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430915/ http://dx.doi.org/10.1097/01.HS9.0000971372.50510.47 |
| _version_ | 1785091074131230720 |
|---|---|
| author | Zhi-Ming, LI Liu, Chuanxu Sun, Peng Tian, Shu Ding, Hao Tao, Rong |
| author_facet | Zhi-Ming, LI Liu, Chuanxu Sun, Peng Tian, Shu Ding, Hao Tao, Rong |
| author_sort | Zhi-Ming, LI |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430915 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309152023-08-17 P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY Zhi-Ming, LI Liu, Chuanxu Sun, Peng Tian, Shu Ding, Hao Tao, Rong Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430915/ http://dx.doi.org/10.1097/01.HS9.0000971372.50510.47 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Zhi-Ming, LI Liu, Chuanxu Sun, Peng Tian, Shu Ding, Hao Tao, Rong P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title | P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title_full | P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title_fullStr | P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title_full_unstemmed | P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title_short | P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY |
| title_sort | p1119: camrelizumab plus low-dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage i/ii natural killer/t-cell lymphoma: a prospective multicenter single-arm study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430915/ http://dx.doi.org/10.1097/01.HS9.0000971372.50510.47 |
| work_keys_str_mv | AT zhimingli p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy AT liuchuanxu p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy AT sunpeng p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy AT tianshu p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy AT dinghao p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy AT taorong p1119camrelizumabpluslowdoseapatinibandpegaspargasefollowedbyradiotherapyfornewlydiagnosedstageiiinaturalkillertcelllymphomaaprospectivemulticentersinglearmstudy |